Apixaban and Blindness transient - a phase IV clinical study of FDA data

Summary:

Blindness transient is reported as a side effect among people who take Apixaban (apixaban), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Atenolol, and have Stroke.

The phase IV clinical study analyzes which people have Blindness transient when taking Apixaban. It is created by eHealthMe based on reports of 60,044 people who have side effects when taking Apixaban from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Blindness transient?

Blindness transient (sudden loss of vision) is found to be associated with 615 drugs and 683 conditions by eHealthMe. Check the latest studies of Blindness transient.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

60,044 people reported to have side effects when taking Apixaban.
Among them, 19 people (0.03%) have Blindness transient.

Could Apixaban cause Blindness transient?

Among these 19 people:

How long have people been on Apixaban when they have Blindness transient? *

What is the gender of people who have Blindness transient when taking Apixaban? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Blindness transient when taking Apixaban? *

What are other drugs people take besides Apixaban? *

What are other side effects people have besides Blindness transient? *

Dizziness: 6 people, 31.58%
Nausea (feeling of having an urge to vomit): 4 people, 21.05%
Fatigue (feeling of tiredness): 4 people, 21.05%
Pain In Extremity: 3 people, 15.79%
Weakness: 3 people, 15.79%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 15.79%
Tongue Disorder (disease of tongue): 3 people, 15.79%
Injection Site Pain: 3 people, 15.79%
Hypoaesthesia Oral (reduced sense of touch or sensation in mouth): 3 people, 15.79%
Dyspnea (difficult or laboured breathing): 3 people, 15.79%

What are the existing conditions these people have? *

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 6 people, 31.58%
Prostate Cancer: 2 people, 10.53%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 10.53%
Age-Related Macular Degeneration: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and have Blindness transient?

- Check whether Blindness transient is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Apixaban:

Apixaban (60,351 reports)

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness transient:

Blindness transient (615 drugs)

Browse all the conditions that are associated with Blindness transient:

Blindness transient (683 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Apixaban) and Apixaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.